The homologous proteins MDM2 and MDMX negatively regulate the tumor suppressor protein p53 by antagonizing p53 transactivation activity and targeting p53 for degradation. MDM2 and MDMX bind to p53 via N-terminal p53-binding domains to control the level of p53. The N-terminal regions of MDM2 and MDMX are modified in vivo under stressed conditions, suggesting that modifications to MDM2/MDMX also may affect the p53-MDM2/MDMX interaction. Ample evidence suggests that the MDM2 lid (residues 1-24) is partially structured and significantly reduces its binding affinity with p53 several fold. Since MDM2 and MDMX possess very similar p53-binding domains but different lids, however, the function of the N-terminal lid of MDMX still remains poorly understood. Using a native chemical ligation technique, the p53-binding domain of MDMX, (1-108)MDMX, and its N-terminal lid (residues 1-23) truncated analogue (24-108)MDMX were chemically synthesized. We comparatively characterized their structures by circular dichroism (CD) spectra, and measured their binding affinities with a panel of p53-derived peptide ligands by fluorescence polarization and surface plasmon resonance assays. Our results indicate that, as opposed to the lid of MDM2, the lid of MDMX has little effect on p53-binding, adopts no structural conformation, and has rare auto-inhibitory function. Different lid modifications of MDM2 and MDMX are functionally different with respect to p53 binding, which should be considered when designing dual specific inhibitors of MDM2 and MDMX.

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.c15-00975DOI Listing

Publication Analysis

Top Keywords

mdm2 mdmx
24
n-terminal lid
12
lid mdmx
12
mdmx
10
p53
8
p53 binding
8
native chemical
8
chemical ligation
8
mdm2
8
p53 n-terminal
8

Similar Publications

PROTACs have emerged as a therapeutic modality for the targeted degradation of proteins of interest (POIs). Central to PROTAC technology are the E3 ligase recruiters, yet only a few of them have been identified due to the lack of ligandable pockets in ligases, especially among single-subunit ligases. We propose that binders of partner proteins of single-subunit ligases could be repurposed as new ligase recruiters.

View Article and Find Full Text PDF

Purpose: Pediatric sarcomas are bone and soft tissue tumors that often exhibit high metastatic potential and refractory stem-like phenotypes, resulting in poor outcomes. Aggressive sarcomas frequently harbor a disrupted p53 pathway. However, whether pediatric sarcoma stemness is associated with abrogated p53 function and might be attenuated via p53 reactivation remains unclear.

View Article and Find Full Text PDF

The treatment of retinoblastoma (RB), a formidable eye cancer that affects infants and children, is not only aimed at saving lives but at preserving ocular function, maintaining optimal visual acuity, and enhancing the overall quality of life. Photodynamic therapy has already been established as a secure and dependable therapeutic modality for the treatment of ocular diseases that effectively preserves ocular function; however, it fails to provide satisfactory outcomes against RB. To address this formidable challenge, groundbreaking advancement is aspired by delving into the genetic characteristics of RB, which initially involves the wild-type p53 pathway but is subsequently suppressed by MDM2 and MDMX.

View Article and Find Full Text PDF

An update patent review of MDM2-p53 interaction inhibitors (2019-2023).

Expert Opin Ther Pat

December 2024

Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Lodz, Poland.

Article Synopsis
  • The p53 tumor suppressor protein is commonly disrupted in cancers through TP53 mutations or MDM2 overexpression, leading to interest in inhibitors that can release p53 for cancer therapy.
  • The article reviews patents and patent applications from 2019 to 2023 for MDM2-p53 interaction inhibitors, categorizing newly discovered compounds into five groups based on their chemical structure.
  • Despite two decades of research and various clinical evaluations, no MDM2-p53 inhibitors have been approved for market use yet, though over ten are still undergoing clinical trials, including some with promising FDA designations.
View Article and Find Full Text PDF
Article Synopsis
  • * Research shows that Mdmx plays an anti-invasive role by stabilizing and activating the RhoA GTPase, especially in the context of NEDD8 pathway inhibitors during cell migration in Xenopus embryos.
  • * The study identifies that while Mdmx promotes RhoA activation, prolonged inhibition of NEDDylation leads to Mdmx degradation by non-NEDDylated Culin4A and the Mdm2 E3-ligase, impacting its anti-invasive effects and hinting at its importance in the effectiveness of NEDD8 pathway inhibitors in
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!